ALGOTHERAPEUTIX
15.12.2020 08:17:14 CET | Business Wire | Press release
France-based biotechnology company AlgoTherapeutix, the developer of an innovative topical treatment for chemotherapy-induced peripheral neuropathy (CIPN), announced today it has received approval from the ethics committee and the regulatory authority in the Czech Republic to initiate a Phase 1 clinical trial with ATX01. The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021.
AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. Given a positive outcome of the approved Phase 1 study, the company intends to initiate Phase 2 by the end of 2021.
Stéphane Thiroloix , Founder & CEO of AlgoTherapeutix, says: “I am thrilled by the entry of ATX01 in clinical development as it represents a great step forward towards providing CIPN patients with a response to the crippling pain they endure.”
Over half of cancer patients treated with chemotherapy - over two million patients in the US and Europe - develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. CIPN is a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists and pain specialists.
Over the last two years, AlgoTherapeutix took ATX01 from exploratory prototype to final formulation, established its pharmacological profile, conducted a full pre-clinical toxicology package, and scaled-up manufacturing to enable clinical supply production. In parallel, AlgoTx firmed-up ATX01’s development pathway via a pre-IND consultation with the FDA and obtained an Orphan Drug Designation from the FDA to explore ATX01’s activity in erythromelalgia.
A recent publication in the “Journal of Pain” describes the exploratory pharmacological impact of high-dose topical amitriptyline in CIPN patients along with the mechanism of action supporting its activity (https://doi.org/10.1016/j.jpain.2020.11.002 )
About AlgoTherapeutix
AlgoTx was founded in 2018 by Stéphane Thiroloix and Olivier Bohuon to develop topical treatments for complex pain and was incubated by Paris Biotech Santé. Their lead programme ATX01 is in clinical development in Chemotherapy-Induced Peripheral Neuropathy. More information at www.algotx.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005352/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ID UNLIMITED Strengthens European Platform With Acquisition of Denmark’s Jet Sport17.6.2026 10:00:00 CEST | Press release
ID UNLIMITED, a European leader in premium equipment personalisation and embellishment services for sports clubs, leagues and global sports brands, has signed an agreement to acquire Jetsport A/S (“Jet Sport”), a provider of personalisation and customisation services headquartered in Viborg, Denmark, specialised in sportswear and workwear. Jet Sport marks the first acquisition under ID UNLIMITED's international expansion strategy since partnering with TowerBrook Capital Partners in April this year. The transaction is expected to close by the end of June 2026, subject to customary conditions. Founded in 1971, Jet Sport is a family-owned business with over five decades of experience in textile embellishment. The company serves sports clubs, sporting goods retailers, workwear suppliers and industrial clients, providing high-quality screen prints, heat transfers and embroideries with approximately 140 employees. Jet Sport has built a reputation for quality, fast turnaround and technical in
Reply Achieves the AWS Business Value Realization Competency17.6.2026 10:00:00 CEST | Press release
Reply [EXM, STAR: REY] announced today that it has achieved the Amazon Web Services (AWS) Business Value Realization Competency. This specialization recognizes Reply as an AWS Partner that helps customers deliver measurable, post-sales business outcomes from their AWS investments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617874809/en/ Reply achieves the Amazon Web Services (AWS) Business Value Realization Competency that recognizes an AWS Partner that helps customers deliver measurable, post-sales business outcomes from their AWS investments. Achieving the AWS Business Value Realization Competency differentiates Reply as an AWS Partner that excels at helping customers define, measure, and achieve business outcomes from their cloud and AI investments. It signals to customers that a Partner has the commitment, trained and certified teams, and a proven track record of delivering measurable outcomes, not just technical
LTM Launches BlueVerse™ on Databricks to Accelerate AI Monetization17.6.2026 09:46:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse for Databricks, a new offering that brings together LTM’s AI ecosystem, BlueVerse™, with Databricks, the Data and AI company, to accelerate AI-driven data monetization. BlueVerse for Databricks is designed to help enterprises drive tangible business outcomes from data and AI investments by addressing critical challenges in the secure and efficient management of data and compute resources, while optimizing business processes and providing pre-built industry solutions to unlock greater value from AI initiatives. LTM BlueVerse helps companies reimagine core business processes such as procure-to-pay, order-to-cash, hire-to-retire, and marketing operations as AI-optimized workflows. It also enables organizations to accelerate time-to-value through pre-built, industry-specific solutions for Manufacturing, Banking, Financial Services, Insurance, Media & Entertainment, and Retail &
Wolters Kluwer Brings Libra AI Workflows into InView Legal for Belgian Legal Professionals17.6.2026 09:00:00 CEST | Press release
Following the integration of InView content in the Libra by Wolters Kluwer legal AI workspace earlier this year, Libra AI functionalities are now also available in InView Legal Belgium via Libra add-in Wolters Kluwer Legal & Regulatory today announced the integration of Libra by Wolters Kluwer AI workflows in InView Legal (formerly known as Jura) in Belgium. This integration brings generative AI features directly into the research workflow of legal professionals and allows a seamless experience without switching between tools. The integration follows the launch of the Libra legal AI workspace in Belgium in February, combining AI with authoritative legal content from InView Legal and supporting lawyers across their full workflow, from research to analysis and document drafting. With the newly launched Libra add-in for InView Legal customers can use Libra’s AI functionalities for drafting, review and analysis in one unified environment, handling their work end-to-end. The solution reflec
Zoya Technologies Launches Clinical AI Terminal Engineered to Operate Without Internet Connectivity17.6.2026 09:00:00 CEST | Press release
ZoyeMed 3.0 Resilience Edition runs the complete Longitudinal Multimodal Model on-device, supporting a full medical episode - triage, examination, 120+ point-of-care tests, and prescription support - in fully disconnected environments Almost every digital health system assumes the internet will be there. Zoya Technologies today launched the ZoyeMed 3.0 Resilience Edition, a clinical AI terminal engineered to deliver a complete medical episode without an internet connection at any stage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617381037/en/ The ZoyeMed 3.0 Resilience Edition - a fully standalone clinical AI terminal engineered to operate without internet connectivity, integrating point-of-care diagnostics, examination tools, and on-device AI in a single 5-square-metre footprint (Photo: AETOSWire) Continuity of care is the first casualty of infrastructure disruption. Disasters, grid instability, and remote deployment
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom